Section Review Central & Peripheral Nervous Systems: Alzheimer's disease and β-amyloid: patent activity between May 1995 and July 1996

References

• SELKOE DJ: Physiological production of the 0-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. (1993) 16:403-409. An important review describing many features of AD and APP processing.
   Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMAN PR et al. AND THE TACRINE STUDY GROUP: A 30 week randomized control-led trial of high-dose tacrine in patients with Alzhe-hner's disease. JAMA (1994) 271:985–991.
   PubMed Web of Science ®Google Scholar
• SCHENK DB, RYDEL RE, MAY R et al.: Therapeutic ap-proaches related to amyloid-13 peptide and Alzheinaer's dlesease. J. Med. Chem. (1995) 38(21):4141–4154. A recent review providing an update on the production of AP and compounds which impact this process.
   Google Scholar
• ABRAHAM CR, SELKOE DJ, POTTER H: Immunochemical Identification of the serine protease inhibitor al-an-tichymotrypsin in the brain amyloid deposits of Alzhe-imer's disease. Cell (1988) 52:487–501.
   PubMed Web of Science ®Google Scholar
• NASLUND J: Characterisation of stable complexes involving apolipoprotein E and the amyloid 13 peptide inAlzhehner's disease brain. Neuron (1995) 15:219-228. ApoE has been implicated as a risk factor for AD and this paper shows that ApoE is also a component of senile plaques.
   Google Scholar
• TROJANOWSKI JQ, SHIN R-W, SCHMIDT ML, LEE VM-Y: Relationship between plaques, tangles and dystrophic processes in Alzheimer's disease. Neurobiol. Aging (1995) 16(3):335–345.
   PubMedGoogle Scholar
• YANKNER BA: Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron (1996) 16:921-932. An excellent review containing an update of APP processing.
   Google Scholar
• PONTE P, GONZALEZ-DEWHITT P, SCHILLING J et al.: A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (1988) 331(11):525–527.
   PubMedGoogle Scholar
• TANZI RE, MCCLATCHEY AI, LAMPERT' ED et al: Protease Inhibitor domain encoded by an amyloid protein pre-cursor naRNA associated with Alzheimer's disease. Na-ture (1988) 331(11):528–530.
   PubMedGoogle Scholar
• ESCH FS, KEIM PS, BEA1 11E EC et al: Cleavage of amyloid peptide during constitutive processing of its precur-sor. Science (1990) 248:1122–1124.
   PubMed Web of Science ®Google Scholar
• WANG R, MESCHIA JF, COTTER RJ, SISODIA SS: Secretion of the 13/A5 amyloid precursor protein. Identification of a cleavage site hi cultured mammalian cells. J. Biol. Chem. (1991) 266(25):16960–16964.
   Google Scholar
• HAASS C, KOO EH, MELLON A, HUNG AY, SELKOE DJ: Targeting of cell-surface 13-amyloid precursor protein to lysosomes: alternative processing into amyloid-bear-ing fragments. Nature (1992) 357(11):500–503.
   PubMedGoogle Scholar
• GOLDE YE, ESTUS S, YOUNKIN LH, SELKOE DJ, YOUNICIN SG: Processing of the amyloid protein precursor to potentially amyloidogenk derivatives. Science (1992) 235:728–730.
   Google Scholar
• IVERSEN LL, MORTISHIRE-SMITH RJ, POLLACK SJ, SHEAR-MAN MS: The toxicity in vitro of 13-atnyloid protein. BiochemJ. (1995) 311:1-16. An excellent review characterising AP neurotoxicity.
   Google Scholar
• PIKE CJ, BURDICK D, WALENCEWICZ AJ, GLABE CG, COTMAN CW: Neurodegeneration induced by 13-amyloid peptides in vitro: the role of peptide assembly. J. Neuro-sci. (1993) 13:1676–1687,
   Google Scholar
• SIMMONS LK, MAY PC, TOMASELLI KJ et al.: Secondary structure of amyloid beta peptide correlates with neuro-toxicity in vitro. Mol, Pharmacol (1994) 45:879–888.
   Google Scholar
• MATTSON MP, TOMASELLI KJ, RYDEL RE: Calcium-desta-bilizing and neurodegenerative effects of aggregated P-arnyloid peptide are attenuated by basic FGF. Brain Res. (1993) 621:35–49.
   PubMed Web of Science ®Google Scholar
• SMITH MA, SAYRE LM, MONNIER VM, PERRY G: Radical AGEing in Alzheimer's disease. Trends Neurosci. (1995) 18(4):172–176.
   PubMedGoogle Scholar
• FROLICH L, RIEDERER P: Free radical mechanisms indementia of Alzheimer type and potential for antioxi-dative treatment. Arzneim. Forsch. Drug Res. (1995) 45(1):443–446.
   PubMedGoogle Scholar
• ARISPE N, POLLARD HB, ROJAS E: Giant multilevel cationchannels formed by Alzheimer disease amyloid 13-protein [AAP-(1-40)lin bilayer membranes. Proc. Natl. Acad. Sci. USA (1993) 90:10573–10577.
   PubMed Web of Science ®Google Scholar
• ARISPE N, ROJAS E, POLLARD HB: Alzheimer disease amyloid (3-protein forms calchun channels in bilayer membranes: blockade by tromethamine and alumi-num. Proc. Natl. Acad. Sci. USA (1993) 90:567–571.
   PubMed Web of Science ®Google Scholar
• BENZI G, MORETTI A: Are reactive oxygen species in-volved in Alzheimer's disease? Neurobiol. Aging (1995) 16(4):661–674.
   Google Scholar
• HAMPEL H, MULLER N: Inflammatory and immunologi-cal mechanisms in Alzheimer's disease. Drug News Per-spect . (1995) 8(10):599–608.
   Google Scholar
• MCGEER PL, MCGEER EG: The inflammatory responsesystem of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. (1995) 21(2):195–218.
   PubMed Web of Science ®Google Scholar
• BUSCIGLIO B, LORENZO A, YEH J, YANKNER BA: A-Amybid fibrils induce tau phophorylation and loss of mi-crotubule binding. Neuron (1994) 14:879-888. This paper reports that treatment of primary neuronal cultures with aggregated Al3 can induce tau hyperphosphorylation.
   Google Scholar
• MARX J: Major setback for Alzheimer's models. Science(1992) 255:1200–1202.
   PubMed Web of Science ®Google Scholar
• GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer's type neuropathology in transgenic mice overexpress-ing V717F A-amyloid precursor protein. Nature (1995) 373:523-527. The most well characterised in vivo model for Alzheimer's disease described to date.
   Google Scholar
• WASCO W, BUPP K, MAGENDANTZ M et al.: Identificationof a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid protein precursor. Proc. Natl. Acad. Sci. USA (1992) 89:10758–10762.
   PubMed Web of Science ®Google Scholar
• SLUNT HH, THINAKARAN G, VON KOCH C et al.: Expres-sion of a ubiquitous, cross-reactive homologue of the mouse A-amyloid precursor protein (APP). J. Biol. Chem. (1994) 269:2637–2644.
   Google Scholar
• VITEK MP, BHATTACHARYA K, CERAMI A: Advanced p,lycation end products contribute to amyloidosis in Alzhehner's disease. Proc. Natl. Acad. Sci. USA (1994) 91:4766–4770.
   PubMed Web of Science ®Google Scholar
• BOLAND K, BEHREN M, CHOI D, MANIAS K, PERLMUTTERDH: The serpin-enzyme complex receptor recognizes soluble, nontoxic atnyloid-A peptide but not aggregated, cytotoxic amyloid-A peptide. J. Biol. Chem. (1996) 271:18032–18044.
   PubMedGoogle Scholar
• HANSON MB, NIELSEN SE, BERG K: Re-examination andfurther development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol Methods (1989) 119:203–210.
   PubMedGoogle Scholar
• HSIAO Kit, BORCHELT DR, OLSON K et al.: Age-relatedCNS disorder and early death in transgenic FVB/N mice overexpressing Alzhemier amyloid precursor proteins. Neuron (1995)15:1203–1218.
   PubMedGoogle Scholar
• JUAN JC, HAYS SJ: Alzheimer's disease and A-amyloid:patent activity between May 1993 and June 1994. Exp. Opin. Tiler. Patents (1994) 4(10):1207–1215.
   Google Scholar